Thinking "outside the medicine cabinet" is paying off in Australia, where a doctor-pharmacist partnership is reducing hospitalizations for heart failure - one of the most expensive conditions to treat - researchers report in Circulation: Heart Failure. In the American Heart Association journal, researchers describe a collaborative model for ensuring heart failure patients take their medicines properly. The rate of hospitalization was cut by 45 percent in the first year of being part of a collaborative medicines review service. "This is the first study to show these benefits in real-world practice rather than in a trial setting, " said Elizabeth E.
Rosiglitazone, a drug used to treat type 2 diabetes, is associated with an increased risk of heart failure and death among older patients compared to a similar drug (pioglitazone), concludes a study published on bmj.com today. As such, the researchers say it is difficult to advocate continued use of rosiglitazone for most patients. Rosiglitazone and pioglitazone belong to a class of drugs called thiazolidinediones and are widely used for the treatment of type 2 diabetes. They help to control blood sugar levels, but both drugs can also cause side effects including weight gain, fluid retention and heart failure. It is unclear whether there are clinically important differences in the cardiac safety of these two drugs, so researchers in Canada compared the risk of heart attack, heart failure and death in patients treated with rosiglitazone and pioglitazone.
Mums-to-be are being advised not to use personal monitors (Doppler devices) to listen to their baby's heartbeat at home over fears that they may lead to delays in seeking help for reduced fetal movements. In this week's BMJ, Dr Thomas Aust and colleagues from the Department of Obstetrics and Gynaecology at Arrowe Park Hospital, Wirral describe the case of a 27 year old woman who presented to their labour ward 32 weeks into her first pregnancy with reduced fetal movements. She had first noted a reduction in her baby's activity two days earlier but had used her own Doppler device to listen to the heartbeat and reassured herself that everything was normal.
New research at The University of Texas Health Science Center at Houston suggests that ancient Chinese herbal formulas used primarily for cardiovascular indications including heart disease may produce large amounts of artery-widening nitric oxide. Findings of the preclinical study by scientists in the university's Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM) appear in the Sept. 15 print issue of the journal Free Radical Biology & Medicine. Nitric oxide is crucial to the cardiovascular system because it signals the inner walls of blood vessels to relax, which facilitates the flow of blood through the heart and circulatory system.
Prolias, a biotechnology company using proprietary Bead BlotTM technology to develop ligand-based affinity resins that purify and target proteins and protein complexes, announced that it has launched its first family of ProSpectrum LigandsTM. These ligands are focused on cardiovascular disease, with ligands that bind High-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), and cardiac Troponin I proteins. The proprietary ProSpectrum LigandsTM utilize chemically synthesized peptide ligands on microscopic chromatography resin. Synthesis protocols enable controlled synthesis of identical peptide ligands, thereby increasing reproducibility performance.
Ankle Blood Flow Test Helps Identify Stroke Survivors Most At Risk For Future Strokes, Heart Attacks And Death
A simple test that measures blood flow through the ankle helps identify people with peripheral artery disease (PAD) before they start showing symptoms, a study led by University of North Carolina at Chapel Hill researchers has found. The study shows that the test, called an ankle brachial index (ABI), may be useful in screening people who have already suffered a stroke or transient ischemic attack (TIA), said Souvik Sen, M.D., director of the UNC Stroke Center and the study's principal investigator. "Stroke and TIA survivors are already at risk of suffering another stroke, TIA, heart attack or death, " Sen said. "Our study found that 26 percent of survivors also had PAD without showing any symptoms, and this group suffered three times more subsequent strokes, heart attacks and deaths than survivors without PAD.